Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients [1]

Clinical Endocrinology

Volumn 63, Issue 4, 2005, Pages 477-478

  Gatta, Blandine ^a   Hau, Doan Huu ^a   Catargi, Bogdan ^a   Roger, Patrick ^a   Tabarin, Antoine ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CABERGOLINE; GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADENOMA; DOSE RESPONSE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; MORBIDITY; MORTALITY; PRIORITY JOURNAL;

ACROMEGALY; ADULT; AGED; ANTINEOPLASTIC AGENTS; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; ERGOLINES; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE;

EID: 26644444556     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2005.02329.x     Document Type: Letter

References (6)

1. Orme, S.M., McNally, R.J., Cartwright, R.A. & Belchetz, P.E. (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. Journal of Clinical Endocrinology and Metabolism, 83, 2730-2734.
2. Melmed, S., Jackson, I., Kleinberg, D. & Klibanski, A. (1998) Current treatment guidelines for acromegaly. Journal of Clinical Endocrinology and Metabolism, 83, 2646-2652.
3. Freda, P.U. (2002) Somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism, 87, 3013-3018.
4. Trainer, P.J. (2003) Lessons from 6 years of GH receptor antagonist therapy for acromegaly. Journal of Endocrinological Investigations, 26, 44-52.
5. Cozzi, R., Attanasio, R., Lodrini, S. & Lasio, G. (2004) Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clinical Endocrinology, 61, 209-215.
6. Marzullo, P., Ferone, D., Di Somma, C., Pivonello, R., Filippella, M., Lombardi, G. & Colao, A. (1999) Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary, 1, 115-120.